Get the Stockscreener App
78.47
1.31%
0.7204
Bridgebio Pharma Inc stock is traded at $78.47, with a volume of 1.40M.
It is up +1.31% in the last 24 hours and up +16.50% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$77.75
Open:
$78.05
24h Volume:
1.40M
Relative Volume:
0.46
Market Cap:
$15.37B
Revenue:
$579.96M
Net Income/Loss:
$-729.89M
P/E Ratio:
-20.95
EPS:
-3.7459
Net Cash Flow:
$-452.02M
1W Performance:
+5.76%
1M Performance:
+16.50%
6M Performance:
+6.06%
1Y Performance:
+81.08%
1-Day Range:
$76.19
$78.90
1-Week Range:
$73.56
$79.25
52-Week Range:
$42.09
$84.94
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Name
Bridgebio Pharma Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO, CA
Compare BBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
78.48 | 15.23B | 579.96M | -729.89M | -452.02M | -3.7459 |
VRTX
Vertex Pharmaceuticals Inc
|
524.65 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.72 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.14 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.74 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.41 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | RBC Capital Mkts | Outperform |
| Mar-10-26 | Initiated | William Blair | Outperform |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-06-26 | Initiated | Morgan Stanley | Overweight |
| Dec-11-25 | Initiated | Bernstein | Outperform |
| Jul-30-25 | Resumed | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-14-25 | Initiated | Jefferies | Buy |
| Jul-09-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-03-24 | Initiated | Oppenheimer | Perform |
| Sep-04-24 | Initiated | Piper Sandler | Overweight |
| Mar-21-24 | Resumed | Raymond James | Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-23 | Initiated | Citigroup | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-18-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-19-23 | Initiated | Evercore ISI | Outperform |
| Feb-06-23 | Initiated | Cowen | Outperform |
| Dec-27-21 | Reiterated | Mizuho | Buy |
| Dec-27-21 | Reiterated | SVB Leerink | Outperform |
| Sep-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| May-21-21 | Initiated | UBS | Buy |
| Mar-22-21 | Reiterated | Goldman | Buy |
| Feb-22-21 | Resumed | JP Morgan | Overweight |
| Feb-09-21 | Resumed | Goldman | Buy |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Neutral |
| May-19-20 | Initiated | BTIG Research | Buy |
| Apr-13-20 | Initiated | H.C. Wainwright | Buy |
| Feb-19-20 | Initiated | Mizuho | Buy |
| Jul-26-19 | Initiated | Raymond James | Outperform |
| Jul-22-19 | Initiated | BMO Capital Markets | Outperform |
| Jul-22-19 | Initiated | Goldman | Buy |
| Jul-22-19 | Initiated | JP Morgan | Overweight |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jul-22-19 | Initiated | Piper Jaffray | Overweight |
| Jul-22-19 | Initiated | SVB Leerink | Outperform |
View All
Bridgebio Pharma Inc Stock (BBIO) Latest News
BridgeBio Pharma’s SWOT analysis: stock gains momentum on pipeline strength - Investing.com
Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider - GlobeNewswire Inc.
BridgeBio seesaws after settlement in Pfizer Vyndamax patent dispute (update) - MSN
Jefferies Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $100 - Moomoo
BridgeBio Pharma reportedly in talks for $1B preferred equity from KKR, Sixth Street - MSN
Price to book forward of BridgeBio Pharma, Inc. – NASDAQ:BBIO - TradingView
If You Invested $1,000 in Bridgebio Pharma (BBIO) - Stock Titan
BBOT SEC FilingsBridgeBio Oncology Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BridgeBio Pharma Raises $933.9 Million Via 7% Convertible Preferred From Sixth Street, HCRx - TradingView
BridgeBio (Nasdaq: BBIO) secures $933.9M in senior convertible preferred equity - Stock Titan
BridgeBio reports kidney function data for acoramidis in ATTR-CM - Investing.com
BridgeBio reports kidney function data for acoramidis in ATTR-CM By Investing.com - Investing.com South Africa
BridgeBio Pharma Announces New Circulation: Heart Failure Analyses Showing Kidney-Protective Effects of Acoramidis in ATTR-CM - Quiver Quantitative
BridgeBio says acoramidis showed kidney protection in ATTR-CM study - Stock Titan
Latham & Watkins Advises BridgeBio on Up to US$1 Billion Preferred Equity Investment, One of the Largest Preferred Investments for Public Biotechs Ever and the Largest in 2026 - Legal Desire Media and Insights
BridgeBio lands $1 billion, mostly from S.F.'s Sixth Street, with three late-stage drugs in hand - The Business Journals
BridgeBio Pharma Announces $1 Billion Convertible Preferred Equity Deal - Moomoo
BridgeBio raises $1 billion in preferred equity - The Pharma Letter
BridgeBio secures up to $1B in preferred equity - MSN
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches - Sixth Street
BridgeBio secures $1 billion in convertible preferred equity By Investing.com - Investing.com South Africa
BridgeBio Pharma | SCHEDULE 13D/A: Others - Moomoo
BridgeBio secures $1 billion in convertible preferred equity - Investing.com
BridgeBio gets $1B from Sixth Street, HCRx for three launches - Stock Titan
BridgeBio gets funding for drug launch; United buys into cell therapy - Yahoo Finance
Global private equity giants continue to increase investments in the innovative pharmaceuticals sector, with firms including KKR injecting $1 billion into BridgeBio. - Moomoo
Market Chatter: KKR, Sixth Street to Invest $1 Billion in BridgeBio Preferred Equity - 富途牛牛
Sixth Street, KKR Provide BridgeBio $1 Billion Preferred Equity - Bloomberg.com
Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential? - Yahoo Finance
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) dropped from Russell 2000 Index - marketscreener.com
BridgeBio: 3 New Drug Approvals In Sight Outweigh Attruby Issues, Still Bullish (BBIO) - Seeking Alpha
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) added to Russell Midcap Value Benchmark - marketscreener.com
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) added to Russell Midcap Growth Benchmark - marketscreener.com
Sector Update: Healthcare - Moomoo
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) dropped from Russell 2000 Growth Benchmark - marketscreener.com
BridgeBio Pharma Meets Primary Endpoint For Achondroplasia Drug in Phase 3 Trial - Moomoo
BridgeBio Pharma, Inc. (BBIO): Investor Outlook Highlights 45.61% Potential Upside Amid Robust Pipeline - DirectorsTalk Interviews
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) added to Russell 1000 Value Benchmark - marketscreener.com
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) added to Russell 1000 Growth Benchmark - marketscreener.com
BridgeBio (BBIO) Reports Positive Phase 3 Results for Infigratin - GuruFocus
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) added to Russell Midcap Index - marketscreener.com
BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia - The Manila Times
BridgeBio Pharma Announces NEJM Publication and ICCBH Presentation of Positive Phase 3 PROPEL 3 Data for Oral Infigratinib in Achondroplasia - Quiver Quantitative
BridgeBio's achondroplasia drug posts NEJM Phase 3 data - Stock Titan
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) dropped from Russell 2000 Dynamic Index - marketscreener.com
BridgeBio Pharma, Inc. Actuals & Estimates (NASDAQ:BBIO) - TradingView
BridgeBio shareholders approve board changes and equity plan - The Globe and Mail
BBIO Forecast — Price Target — Prediction for 2027 - TradingView
BridgeBio Pharma Adopts Third Amended 2021 Stock Option and Incentive Plan Following Shareholder Approval - Minichart
BridgeBio Pharma (NASDAQ: BBIO) shareholders approve directors and add 2M plan shares - Stock Titan
BridgeBio Pharma, Inc. Announces the Resignation of Randal W. Scott as Class I Director, Effective as of June 22, 2026 - marketscreener.com
Bridgebio Pharma Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bridgebio Pharma Inc Stock (BBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cook Jennifer E. | Director |
Jun 24 '26 |
Sale |
70.00 |
37,167 |
2,601,690 |
8,383 |
| Cook Jennifer E. | Director |
Jun 23 '26 |
Sale |
68.57 |
2,196 |
150,580 |
8,383 |
| Valantine Hannah | Director |
Jun 22 '26 |
Option Exercise |
41.73 |
2,808 |
117,178 |
14,263 |
| Valantine Hannah | Director |
Jun 22 '26 |
Sale |
68.00 |
2,808 |
190,944 |
11,455 |
| Valantine Hannah | Director |
Jun 23 '26 |
Sale |
68.57 |
2,196 |
150,580 |
9,259 |
1.47%
2.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):